Chimeric Therapeutics Ltd (OTCPK:CHMMF)
$ 0.001 -0.029 (-96.67%) Market Cap: 5.90 Mil Enterprise Value: 6.23 Mil PE Ratio: 0 PB Ratio: 2.00 GF Score: 0/100

Chimeric Therapeutics Ltd at NWR Communications Virtual Conference Transcript

May 02, 2022 / 12:50AM GMT
Max Donne
NWR Communications - Analyst

Good morning and welcome back to day one of NWR's Virtual Investor Conference Series 11. My name is Max Donne, and I will be your host for today.

Up next this morning, we have Chimeric Therapeutics. Chimeric is developing groundbreaking CAR T cell therapies for solid tumor based on scientific research conducted by leading US CAR T experts.

This morning, we have Chimeric's CEO, Jennifer Chow presenting. (Conference Instructions)

Jennifer, I'll now hand it over to you.

Jennifer Chow
Chimeric Therapeutics Pty Limited - CEO and MD

Thanks, Max. Good morning, everybody. Thank you so much for taking the time to join me today. I hope that I will be able to provide a little bit of update for those of you that know us well and some information for those of you that were new too.

Chimeric Therapeutics is a clinical-stage cell therapy company, and we have an incredibly exciting overall investment offer at the moment. We have multiple assets with positive Phase 1 clinical signals. So both are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot